Alexion Pharmaceuticals’ $40 billion sale to AstraZeneca (Nasdaq: AZN) and Immunomedics’ $20 billion sale to Gilead Sciences (Nasdaq: GILD) last year helped set a high bar for healthcare deal expectations. Will the party keep going? Trends including vertical integration and telemedicine are propelling this year’s deal flow thus far.
To read the entire story, you must be logged in.
Please log in now or register with us.
